In this same secondary analysis of the APEX trial, the initial signs of cerebral AD‐related brain changes occurred across multiple modalities, including MRI measures of brain structure, which occurred in the absence of significant differences in body weight, body composition, or apolipoprotein epsilon 4 (APOE4) genotype status (carrier or noncarrier). Here, APOE is linked to Alzheimer disease.